Table 1.
Characteristics of currently licensed prophylactic HPV vaccines.
| Vaccine Brand Name | Valency and VLP Types | Manufacturer and Licensure Date | Adjuvant | Expression System |
|---|---|---|---|---|
| Gardasil® | Quadrivalent HPV-6, HPV-11, HPV-16, HPV-18 |
Merck & Co. 2006 |
Amorphous aluminium hydroxyphosphate sulphate 225 µg | Yeast Saccharomyces cerevisiae expressing L1 |
| Cervarix® | Bivalent HPV-16, HPV-18 |
GlaxoSmithKline 2007 |
AS04 0.5 mg aluminium hydroxide and 50 µg 3-0-desacyl-4’ monophosphoryl lipid A |
Insect cell line infected with recombinant baculovirus encoding L1 |
| Gardasil 9® | Nonavalent HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, HPV-58 |
Merck & Co. 2014 |
Amorphous aluminium hydroxyphosphate sulphate 500 µg | Yeast Saccharomyces cerevisiae expressing L1 |
| Cecolin® | Bivalent HPV-16, HPV-18 |
Xiamen Innovax Biotechnology 2020 |
Aluminium hydroxide 208 µg | Escherichia coli expressing L1 |
| Walvax recombinant HPV vaccine | Bivalent HPV-16, HPV-18 |
Shanghai Zerun Biotechnology (Subsidiary of Walvax Biotechnology) 2022 |
Aluminium phosphate | Yeast Pichia Pastoris expressing L1 |